Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Investor Presentation (September 2006)
17 slides from Neurocrine Biosciences's investor presentation, Sep 13, 2006
Slide 1: Website09-13-06.ppt
Website09-13-06.ppt
Slide 2: Forward-looking risk statement
This presentation includes early and late stage clinical data and projections based thereon that involve a number of risks and uncertainties. These risks include the specific risk that the clinical development of the products discussed will not successfully proceed to later stage clinical trials or
Slide 3: Development Portfolio
Development Portfolio Preclinical Phase 1 Phase 2 Phase 3 Registration Indiplon1 Insomnia NBI-56418 - GnRH Antagonist Endometriosis NBI-69734 - CRF-R2 Agonist ADHF NBI-6024 - Altered peptide ligand Type I Diabetes CRF-R1 Antagonist (1)2 Gastrointestinal Disorders Anxiety Depression CRF-R1 Antagonist
Slide 4: Indiplon Regulatory Update
Indiplon Regulatory Update • Results of End-of-Review FDA meeting for Indiplon (IR) capsules - FDA requested supplemental pharmacokinetic/Food Effect study (several meal types) - No other clinical trials requested - Re-submission before end of Q2 2007 • Indiplon (MR) tablets meeting with FDA schedul
Slide 5: GnRH Antagonist for Endometriosis Offers safety and efficacy
GnRH Antagonist for Endometriosis Offers safety and efficacy GnRH GnRH agonists antagonist OCPs MPA Estradiol Concentration 0 20 40 60 80 (pg/ml) Effect on Atrophy of lesions Growth of lesions endometriosis Effect on bone Bone loss occurs Other metabolic effects Hot flashes Fewer hot Fewer hotflashe
Slide 6: Study 0501: NBI-56418
Study 0501: NBI-56418 — Objective • Safety, efficacy and dose-finding study of NBI-56418 in patients with endometriosis — Design • Phase IIa randomized, double-blind, placebo-controlled parallel group, 12- week treatment with 12-week safety follow-up; three dose groups equal randomization (n=76 tota
Slide 7: NBI 56418-0501: Preliminary Data at Week 12
NBI 56418-0501: Preliminary Data at Week 12 Mean Baseline Characteristics Placebo 75 mg 150 mg Age (years) 30.2 32.8 30.5 VAS 31.2 34.9 33.5 CPSSS 9.1 8.5 8.0 Reduction in Scores from Baseline Placebo 75 150 Analysis mg mg VAS 5.3 13.9 21.1* Repeated measures ITT 13.1 25.8 37.4* Peak VAS (severe pai
Slide 8: VAS: Mean Change From Baseline
VAS: Mean Change From Baseline Website09-13-06.ppt
Slide 9: Reduction in "Worst Pain" Mean Change In Monthly VAS
Reduction in “Worst Pain” Mean Change In Monthly VAS (95% CI) Website09-13-06.ppt
Slide 10: NBI 56418-0501: Data at Week 12
NBI 56418-0501: Data at Week 12 Safety Assessment (12-week treatment) Day 2 to 7 of Menstrual Cycle Placebo 75 mg 150 mg Placebo QD n=24 Discontinuations 18% 20% 17% Screening Run in M 75 mg QD n=24 Most common 7% 20% 34% 150 mg QD n=24 AE: Nausea* Hot Flashes ** 61% 56% 52% N-telopeptide CPSSS CPSS
Slide 11: NBI 56418 for Endometriosis
NBI 56418 for Endometriosis — Phase II “Proof of Concept” study successful in demonstrating safety and tolerability over 12 weeks of treatment and 12 weeks follow up — Reduction in pain evident on both CPSSS and VAS at 150 mg/day • Marked reduction in maximum VAS or “worst pain” • Dysmenorrhea and n
Slide 12: GnRH Program Status
GnRH Program Status Study 0301 PK/PD effects of NBI-56418 in females 9 Tolerability of single and 7 day dosing in females 9 Study 0402 PK/PD effects of NBI-56418 in males 9 Tolerability of single dosing in males 9 Study 0405 PK/PD effects of 42 days NBI-56418 in females 9 Tolerability of 42 days dos
Slide 13: Urocortin 2 Targeted ADHF patient population
Urocortin 2 Targeted ADHF patient population ADHF Admissions1 1M primary diagnosis 3M secondary diagnosis 25%2 75% of patients2 Diastolic dysfunction Systolic dysfunction Diuretics 98%2 2%2 Vasodilators Natrecor Stable Unstable Inotropes hemodynamics hemodynamics Diuretics Diuretics Addressable ADHF
Slide 14: Urocortin 2 Summary of Results to Date
Urocortin 2 Summary of Results to Date Intravenous infusion of Urocortin 2 into healthy males and stable CHF produces: – Rapid and marked increase in cardiac output with minimal effect on heart rate in stable CHF – Decreased systemic vascular resistance with decreased mean arterial blood pressure –
Slide 15: CRF Antagonists Current Status of NBI / GSK Compounds
CRF Antagonists Current Status of NBI / GSK Compounds 2006 2007 2008 2009 Lead Compound Anxiety & Phase I Phase II Late Phase II PoC Early Phase III Depression Phase II Late Phase II IBS Phase I PoC Early Phase III Backup Compound Phase I Phase II Studies PoC Different Series High Exposure Safety fr
Slide 16: Financial Highlights
Financial Highlights Quarter Ending Year Ending June 30, 2006 Dec. 31, 2005 Revenues Revenues and and other $ 11.1 million $ 126.8 million other income income Operating Operating and and other other Expenses Expenses $ 38.5 million $ 149.0 million Net Net income income (loss) (loss) $ (27.4) million
Slide 17: Website09-13-06.ppt
Website09-13-06.ppt
Neurocrine Biosciences — Investor Presentation (September 2006) on 6ix